Title of Profil	An Anti-CD40 Small-Inhibitory RNA for the Treatment of Immune Inflammatory Disorders and Prevention of Post-Tranplant Ischemia/Reperfusion Injury and Organ Rejection
Reference	12 ES 252K 3P6B
Country of origin	Spain
Offers/Requests	Offer
Entry/Update	2012-06-07 / 2013-05-13
Status	update

Abstract

A Spanish biotech company is looking for a biotechnology or large pharmaceutical company partner for the clinical development of an anti-CD40 small-inhibitory RNA (CD40-siRNA) with proven efficacy in in vivo models of autoimmune nephritis and prevention of post-transplant renal ischemia/reperfusion injury. It is ready to enter pre-clinical GLP stage regulatory development with a view to conduct clinical proof-of-principle studies in patients with Lupus Nephritis as the market lead indication.

Details

The Spanish biotechnology company has a lead compound for the treatment of autoimmune nephritis and prevention of post-transplant renal ischemia/reperfusion injury ready to enter pre-clinical GLP regulatory development.ZY-11 is a cholesterol-conjugated anti-CD40-siRNA whose effectiveness in NZB/W mice with autoimmune nephritis has been clearly established (submitted for publication), as shown by the prevention of proteinuria as effectively as cyclophosphamide (CYP), reduced anti-dsDNA antibodies, improved histopathological renal scores, and markedly reduced interstitial CD3+ and plasma cell infiltrates, as well as glomerular C3 and IgG deposits. ZY-11 has also been shown to prevent renal dysfunction due to ischemia/reperfusion injury and acute humoral transplant rejection in vivo.Biotechnology or pharmaceutical companies interested in further developing this lead compound under license or cooperation agreement are sought.Innovative Aspects:Effective post-transcriptional gene-silencing is specifically achieved through the design of sequence-specific small inhibitory RNAs which lead to the selective degradation of target mRNAs thus precluding the synthesis of their cognate protein product. ZY-11 targets the immune co-stimulatory molecule CD40 as a key activator of undesirable autoimmune as well as allo-immune responses.

Technology sector	- Clinical Research, Trials - Gene - DNA Therapy - Pharmaceutical Products / Drugs - Cellular and Molecular Biology
Market application	- Medical genetic engineering applications - Other Genetic Engineering - Therapeutic - Pharmaceuticals/fine chemicals
Stage of development	Development phase - Laboratory tested
Patent Rights (IPR)	Patent(s) granted
Cooperation type	- License Agreement - Joint further development - Testing of new applications - Adaptation to specific needs - Financial Resources Type of partner sought: Clinical stage biotechnology company or large pharmaceutical company.Specific area of activity of the partner: Pharmaceutical drug development and commercialization including biotherapeutic agents. Task to be performed by the partner sought: Conduct/support IND/CTA/CTX enabling pre-clinical GLP studies; Conduct/support subsequent clinical proof-of-principle studies in patients with Lupus Nephritis and/or other agreed upon indications.
Organisation type	Industry

We only react to expressions of interest in Swiss profiles and/or made by organisations based in Switzerland Would you like to contact this organisation?   Yes

You are not based in Switzerland? You are not interested in a Swiss profiles? Find your local access point on the Network website. This technology profile does not fit your requirements? You are searching for a tailor made solution? You are interested to promote your own technology profile? => Contact us now! => In short time we can find suitable partners Further Details